Shanghai OPM Biosciences Co., Ltd. (SHA:688293)
China · Delayed Price · Currency is CNY 48.29
-3.75 (-7.21%)
At close: May 12, 2026
Shanghai OPM Biosciences Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 65.58 | 41.02 | 21.05 | 54.04 | 105.37 | 60.39 |
Depreciation & Amortization | 50.41 | 50.41 | 45.68 | 36.83 | 33.85 | 28.19 |
Other Amortization | 11.01 | 11.01 | 12.39 | 5.88 | 5.17 | 4.07 |
Loss (Gain) From Sale of Assets | - | - | -0.09 | - | -0.29 | - |
Asset Writedown & Restructuring Costs | 21.39 | 21.39 | 7.51 | 0.02 | 0 | 0.02 |
Loss (Gain) From Sale of Investments | -26.7 | -26.7 | -18.25 | -14.59 | -5.81 | -4.18 |
Provision & Write-off of Bad Debts | - | - | 6.92 | 6.42 | 4.76 | 0.31 |
Other Operating Activities | -62.09 | 10.45 | -0.6 | 1.99 | 3.01 | 5.11 |
Change in Accounts Receivable | 12.2 | 12.2 | -39.23 | -24.83 | -46.04 | -6.3 |
Change in Inventory | -18.53 | -18.53 | -9.41 | -5.62 | -10.56 | -21.26 |
Change in Accounts Payable | 4.84 | 4.84 | 38.54 | -8.16 | 16.82 | 40.52 |
Change in Other Net Operating Assets | 4.6 | 4.6 | 5.5 | 6.87 | 5.79 | 7.87 |
Operating Cash Flow | 55.41 | 103.39 | 69.25 | 57.95 | 111.62 | 114.63 |
Operating Cash Flow Growth | -48.16% | 49.30% | 19.49% | -48.08% | -2.62% | 3478.75% |
Capital Expenditures | -57.37 | -56.07 | -120.86 | -77.55 | -146.96 | -105.98 |
Sale of Property, Plant & Equipment | 0.07 | - | - | - | 6.78 | - |
Cash Acquisitions | 107.64 | - | - | 0.02 | - | - |
Investment in Securities | -44.7 | -45 | -253.73 | -73.26 | -283.28 | -38 |
Other Investing Activities | 684.66 | -56.58 | 4.05 | 1.25 | 37.87 | 3.99 |
Investing Cash Flow | 690.3 | -157.64 | -370.54 | -149.53 | -385.59 | -139.99 |
Long-Term Debt Issued | - | 0.12 | - | - | 32.34 | 42.82 |
Long-Term Debt Repaid | - | -0.12 | -11.3 | -45.42 | -62.79 | -21.6 |
Net Debt Issued (Repaid) | - | - | -11.3 | -45.42 | -30.45 | 21.22 |
Issuance of Common Stock | 361.61 | 6.55 | - | - | 1,523 | - |
Repurchase of Common Stock | - | - | -37.25 | -13.75 | - | - |
Common Dividends Paid | -48.83 | -48.83 | -51.22 | -73.83 | -2.08 | -1.8 |
Other Financing Activities | -14.44 | -14.79 | 0.13 | - | -15.74 | 0.2 |
Financing Cash Flow | 298.34 | -57.06 | -99.64 | -133.01 | 1,474 | 19.62 |
Foreign Exchange Rate Adjustments | -16.85 | -5.35 | 2.42 | 0.95 | 2.35 | -0.24 |
Net Cash Flow | 1,027 | -116.66 | -398.51 | -223.64 | 1,203 | -5.99 |
Free Cash Flow | -1.96 | 47.32 | -51.61 | -19.59 | -35.34 | 8.64 |
Free Cash Flow Margin | -0.43% | 13.33% | -17.36% | -8.06% | -12.01% | 4.06% |
Free Cash Flow Per Share | -0.01 | 0.42 | -0.44 | -0.17 | -0.35 | 0.10 |
Cash Income Tax Paid | 54.15 | 51.72 | 29.9 | 11.38 | 28.47 | 13.42 |
Levered Free Cash Flow | 818.21 | -332.16 | -48.83 | -38.18 | -100.94 | -34.34 |
Unlevered Free Cash Flow | 818.21 | -332.16 | -46.88 | -36.16 | -97.83 | -31.35 |
Change in Working Capital | -4.18 | -4.18 | -5.37 | -32.64 | -34.44 | 20.7 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.